# A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control

Study · id `cardio:ct-nct03242018` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03242018](<https://clinicaltrials.gov/study/NCT03242018>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03242018

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 277 participants.

## Technical summary

Registry record NCT03242018. Randomized; quadruple masking; primary purpose treatment. Start 2017-08-16 (actual); primary completion 2019-05-16 (actual). Results posted on 2021-06-25.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 277 participants (enrolled count; ClinicalTrials.gov record NCT03242018, source copy `cardio:ctgov-nct03242018-2021-06-25`, retrieved 2026-10-26)
- Started: 2017-08-16 (actual) (ClinicalTrials.gov record NCT03242018, source copy `cardio:ctgov-nct03242018-2021-06-25`, retrieved 2026-10-26)
- Primary completion: 2019-05-16 (actual) (ClinicalTrials.gov record NCT03242018, source copy `cardio:ctgov-nct03242018-2021-06-25`, retrieved 2026-10-26)
- Completion: 2019-12-11 (actual) (ClinicalTrials.gov record NCT03242018, source copy `cardio:ctgov-nct03242018-2021-06-25`, retrieved 2026-10-26)
- Results first posted: 2021-06-25 (ClinicalTrials.gov record NCT03242018, source copy `cardio:ctgov-nct03242018-2021-06-25`, retrieved 2026-10-26)
- Countries: United States; Argentina; Brazil; Colombia; Germany; Hungary; Israel; Italy; Mexico; Poland; Romania; Russia; South Africa; Spain; Ukraine (ClinicalTrials.gov record NCT03242018, source copy `cardio:ctgov-nct03242018-2021-06-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03242018-2021-06-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
- Acronym: SOTA-CKD4
- Condition: Type 2 Diabetes Mellitus
- Condition: Chronic Kidney Disease Stage 4
- Intervention (Drug): Placebo
- Intervention (Drug): Sotagliflozin
- Lead sponsor: Lexicon Pharmaceuticals
- Lead sponsor class: INDUSTRY
- Collaborator: Sanofi
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Lexicon Pharmaceuticals (`cardio:org-lexicon-pharmaceuticals`)
- Registry lists this organization as a collaborator: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment (`cardio:pubmed-34338408`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 948ce1d3cc8ee1d124daa2bd6b80afb101d3db7004bf9cb3c9ebc9351a91c4ab
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
